Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - duloxetine hydrochloride, quantity: 33.65 mg - capsule, enteric - excipient ingredients: hypromellose phthalate; triethyl citrate; brilliant blue fcf; purified talc; hypromellose; gelatin; titanium dioxide; sucrose; maize starch; propylene glycol; ethanol; indigo carmine; butan-1-ol; isopropyl alcohol; iron oxide yellow; shellac; strong ammonia solution - duloxetine capsules are indicated for the treatment of major depressive disorder (mdd). treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - clindamycin hydrochloride, quantity: 162.868 mg - capsule, hard - excipient ingredients: lactose; purified talc; microcrystalline cellulose; povidone; magnesium stearate; sodium starch glycollate; titanium dioxide; brilliant blue fcf; purified water; gelatin; sodium lauryl sulfate; tartrazine; propylene glycol; ethanol; isopropyl alcohol; shellac; tert-butyl alcohol; sodium hydroxide - clindamycin lu (clindamycin hydrochloride) capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.,clindamycin lu capsules are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci.,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate.,anaerobes:,serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection. streptococci: serious respiratory tract infections; serious skin and skin structure infections, septicaemia,staphylococci: serious respiratory tract infections; serious skin and skin structure infections; septicaemia; acute haematogenous osteomyelitis,pneumococci: serious respiratory tract infections,adjunctive therapy: in the surgical treatment of chronic bone and joint infections due to susceptible organisms. indicated surgical procedures should be performed in conjunction with antibiotic therapy.,bacteriological studies should be performed to determine the causative organisms and their susceptibility to clindamycin.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - clindamycin hydrochloride, quantity: 162.87 mg - capsule, hard - excipient ingredients: gelatin; titanium dioxide; lactose monohydrate; purified talc; magnesium stearate; maize starch; shellac; iron oxide black - clindamycin hydrochloride capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin capsules are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. anaerobes serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection. streptococci serious respiratory tract infections; serious skin and skin structure infections, septicaemia. staphylococci serious respiratory tract infections; serious skin and skin structure infections; septicaemia; acute haematogenous osteomyelitis. pneumococci serious respiratory tract infections. adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. indicated surgical procedures should be performed in conjunction with antibiotic therapy. bacteriological studies should be performed to determine the causative organisms and their susceptibility to clindamycin.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - duloxetine hydrochloride, quantity: 33.65 mg - capsule, enteric - excipient ingredients: hypromellose; purified talc; gelatin; sucrose; indigo carmine; hypromellose phthalate; triethyl citrate; titanium dioxide; maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; iron oxide yellow; shellac; strong ammonia solution - duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad). duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - duloxetine hydrochloride, quantity: 67.3 mg - capsule, enteric - excipient ingredients: gelatin; sucrose; purified talc; hypromellose phthalate; triethyl citrate; indigo carmine; titanium dioxide; hypromellose; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; maize starch - duloxetine capsules are indicated for the treatment of major depressive disorder (mdd).,treatment of diabetic peripheral neuropathic pain (dpnp). treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - duloxetine hydrochloride, quantity: 67.3 mg - capsule, enteric - excipient ingredients: gelatin; sucrose; indigo carmine; triethyl citrate; titanium dioxide; purified talc; hypromellose phthalate; hypromellose; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; maize starch - duloxetine capsules are indicated for the treatment of major depressive disorder (mdd).,treatment of diabetic peripheral neuropathic pain (dpnp). treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - duloxetine hydrochloride, quantity: 33.65 mg - capsule, enteric - excipient ingredients: hypromellose; sucrose; gelatin; triethyl citrate; titanium dioxide; hypromellose phthalate; purified talc; indigo carmine; maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; iron oxide yellow; shellac; strong ammonia solution - duloxetine capsules are indicated for the treatment of major depressive disorder (mdd).,treatment of diabetic peripheral neuropathic pain (dpnp). treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - duloxetine hydrochloride, quantity: 33.65 mg - capsule, enteric - excipient ingredients: titanium dioxide; triethyl citrate; hypromellose phthalate; sucrose; indigo carmine; hypromellose; gelatin; purified talc; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; iron oxide yellow; shellac; strong ammonia solution; maize starch - duloxetine capsules are indicated for the treatment of major depressive disorder (mdd).,treatment of diabetic peripheral neuropathic pain (dpnp). treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - duloxetine hydrochloride, quantity: 67.3 mg - capsule, enteric - excipient ingredients: titanium dioxide; gelatin; hypromellose; purified talc; hypromellose phthalate; triethyl citrate; indigo carmine; sucrose; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; maize starch - duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - temozolomide, quantity: 250 mg - capsule, hard - excipient ingredients: sodium lauryl sulfate; lactose; stearic acid; gelatin; titanium dioxide; sodium starch glycollate; tartaric acid; colloidal anhydrous silica; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - temodal capsules are indicated for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment; recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy. temodal capsules are also indicated as first line treatment for patients with advanced metastatic malignant melanoma.